Purespring Therapeutics

[{"orgOrder":0,"company":"Purespring Therapeutics","sponsor":"SwanBio Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"AAV-based Gene Therapy","moa":"","graph1":"Neurology","graph2":"Discovery","graph3":"Purespring Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Purespring Therapeutics \/ SwanBio Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Purespring Therapeutics \/ SwanBio Therapeutics"},{"orgOrder":0,"company":"Purespring Therapeutics","sponsor":"Charles River Laboratories International","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"AAV-based Gene Therapy","moa":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"Purespring Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Purespring Therapeutics \/ Charles River Laboratories International","highestDevelopmentStatusID":"4","companyTruncated":"Purespring Therapeutics \/ Charles River Laboratories International"},{"orgOrder":0,"company":"Purespring Therapeutics","sponsor":"Sofinnova Partners","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Series B Financing","leadProduct":"PS-002","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Purespring Therapeutics","amount2":0.11,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Purespring Therapeutics \/ Sofinnova Partners","highestDevelopmentStatusID":"14","companyTruncated":"Purespring Therapeutics \/ Sofinnova Partners"}]